Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 6 for:    stanford treg

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01660607
Recruitment Status : Recruiting
First Posted : August 8, 2012
Last Update Posted : April 22, 2019
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Everett Meyer, Stanford University

Brief Summary:
For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with a T cell depleted graft, the infusion of naturally occurring regulatory T cells with conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and improving immune reconstitution.

Condition or disease Intervention/treatment Phase
Myeloid Leukemia, Chronic Acute Myelogenous Leukemia Myelodysplastic Syndromes (MDS) Lymphoma, Non-Hodgkin Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg) Phase 1 Phase 2

Detailed Description:

Primary Objectives:

  • To determine the efficacy, safety and feasibility of administration of several dose combinations of conventional T cells (Tcon) and regulatory T cells (Treg) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) with HLA matched donors (related or unrelated) using a T cell depleted graft [CD34+ hematopoietic progenitor cells ("CD34+ HSPC")], without immune suppression.
  • To determine the maximum tolerated dose of infused regulatory and conventional T cells in the matched donor setting
  • To determine 1 year event free survival (EFS) post HCT

Secondary Objectives:

  • To determine the 1 year OS in patients undergoing allogeneic HCT with matched donors.
  • To measure the incidence and severity of acute and chronic graft vs host disease (GvHD)
  • To measure incidence of serious infections

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1-2 Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
Study Start Date : December 2011
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Experimental: Dose escalation
For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg)
A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
Other Name: Purified regulatory T cells




Primary Outcome Measures :
  1. GvHD free Relapse free Survival (GRFS) [ Time Frame: 12 months ]
    GvHD-free is defined as no GvHD symptoms, and relapse free survival is defined as survival at 12 months without relapse.


Secondary Outcome Measures :
  1. Dose-limiting toxicity (DLT) [ Time Frame: 28 days ]

    Dose-limiting Toxicity (DLT) was assessed as:

    • Absolute neutrophil count <500/µL, to 28 day
    • Cytokine release syndrome/acute infusion reactions as CTCAE Grade 3 to 5
    • Grade 3 to 4 acute GvHD. GvHD was staged as follows:

      • 1: Skin: rash <25%. Liver: bilirubin (BIL) 2-3mg/dL. Gut: diarrhea (DIA) 500-1000 mL/day
      • 2: Skin: rash 25-50%. Liver: BIL 3-6mg/dL. Gut: DIA 1001-1500 mL/day
      • 3: Skin: rash > 50%. Liver: BIL 6-15mg/dL. Gut: DIA >1501-2000 mL/day
      • 4: Skin: generalized erythroderma. Liver: BIL >15mg/dL. Gut: DIA >2001 mL/day GvHD was graded as follows.
      • 1: Skin Stage 1-2; No Liver stage; No Gut stage
      • 2: Skin Stage 1-3 ; Liver Stage 1; +/- Gut Stage 1
      • 3: Skin Stage 2-3, Liver Stage 2-4; +/- Gut Stage 2-3
      • 4: Skin Stage 2-4; Liver Stage 2-4; +/- Gut Stage 2-4 The outcome is reported as the number of participants who received both Treg and Tcon cell infusions and had DLT events, per treatment level, a number without dispersion.

  2. Overall Survival (OS) [ Time Frame: 1 year ]
    Overall Survival (OS) at 1 year was assessed as the number of participants per treatment level that received the hematopoietic cell transplant (HCT), and remained alive 12 months later, a number without dispersion.

  3. Incidence and Severity of Chronic GvHD [ Time Frame: 2 years ]

    Incidence and severity of chronic GvHD wil be assessed in participants who received the hematopoietic cell transplant (HCT).

    Stage of chronic GvHD was assessed as follows.

    • Stage 1: Skin: rash <25% of skin. Liver: bilirubin 2-3mg/dL. Gut: diarrhea 500-1000 mL/day
    • Stage 2: Skin: rash 25-50% of skin. Liver: bilirubin 3-6mg/dL. Gut: diarrhea 1001-1500 mL/day
    • Stage 3: Skin: rash > 50% of skin. Liver: bilirubin 6-15mg/dL. Gut: diarrhea >1501-2000 mL/day
    • Stage 4: Skin: generalized erythroderma. Liver: bilirubin >15mg/dL. Gut: diarrhea >2001 mL/day Grade of chronic GvHD was determined as follows.
    • Grade 1: Skin Stage 1-2; No Liver stage; No Gut stage
    • Grade 2: Skin Stage 1-3 ; Liver Stage 1; +/- Gut Stage 1
    • Grade 3: Skin Stage 2-3, Liver Stage 2-4; +/- Gut Stage 2 to 3
    • Grade 4: Skin Stage 2-4; Liver Stage 2-4; +/- Gut Stage 2 to 4 The outcome is reported as the number of participants by cGvHD grade and treatment level, a number without dispersion.

  4. Incidence of Serious Infections [ Time Frame: 24 months ]
    The outcome is reported as the number of serious infections per treatment level, in participants who received the hematopoietic cell transplant (HCT), a number without dispersion.

  5. Concomitant Single-agent Immunosuppression [ Time Frame: 2 years ]
    During Phase 2, stage 1, concomitant single-agent immunosuppression will be assessed as in participants receiving fresh Treg cells. The outcome is reported as number of such participants who received single-agent immunosuppression, by treatment level, a number without dispersion.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   13 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Recipient Inclusion Criteria

  1. Patients with the following diseases that are histopathologically confirmed are eligible

    • Acute leukemia, primary refractory or beyond CR1, or minimal residual disease (MRD) positivity.
    • High risk acute myeloid leukemia in CR1 with any of the following features:
    • Complex karyotype(≥3 clonal chromosomal abnormalities)
    • Any of the following high risk chromosomal abnormalities:

      • Monosomal karyotype (-5, 5q-, -7, 7q-)
      • t(11q23), t(9;11), inv(3), t(3;3) t(6;9) t(9;22)
      • Normal karyotype with fms-like tyrosine kinase 3 (FLT3)-ITD mutation
    • Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
    • Myelodysplastic syndromes
    • Myeloproliferative syndromes
    • Non-Hodgkin lymphoma with poor risk features not suitable for autologous HCT
  2. Age ≥18 yo and ≤ 60 yo for patients in Cohort 1 only. At the start of Cohort 2A and beyond, eligibility will be expanded to allow pediatric patients age ≥ 13 yo.
  3. Cardiac ejection fraction ≥ 45%
  4. Lung diffusion capacity ≥ 50%
  5. Calculated creatinine clearance ≥ 50 cc/min
  6. Serum glutamic-pyruvic transaminase( SGPT) and serum glutamic-oxaloacetic transaminase (SGOT) ≤ 3.0 x ULN (Upper limit of normal), unless elevated secondary to disease.
  7. Total bilirubin ≤ 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded
  8. Availability of a HLA matched donor (related or unrelated) defined by Class I (HLA-A and B) serologic typing (or higher resolution) and Class II (HLA DRB1) molecular typing. An HLA matched donor is defined for this study to be a sibling that is HLA matched 6/6; or an unrelated donor that is HLA matched 6/6 or 5/6. A sibling may be a "half sibling."
  9. Karnofsky performance status ≥70%

Recipient Exclusion Criteria

  1. Seropositive for any of the following:

    HIV ab; hepatitis B sAg; hepatitis C ab

  2. Prior myeloablative therapy or hematopoietic cell transplant
  3. Candidate for autologous transplant
  4. HIV positive
  5. Active uncontrolled bacterial, viral or fungal infection, defined as currently taking antimicrobial therapy and progression of clinical symptoms.
  6. Uncontrolled central nervous system (CNS) disease involvement
  7. Pregnant or a lactating female
  8. Positive serum or urine beta human chorionic gonadotropin (HCG) test in females of childbearing potential within 3 weeks of registration
  9. Psychosocial circumstances that preclude the patient being able to go through transplant or participate responsibly in follow up care

Donor Inclusion Criteria

  1. Age ≥13 yo and ≤ 75 years
  2. Karnofsky performance status of ≥ 70% defined by institutional standards
  3. Seronegative for HIV 1 RNA (polymerase chair reaction (PCR); HIV 1 and HIV 2 ab (antibody); HTLV 1 and HTLV 2 ab; PCR+ or sAg (surface antigen) hepatitis B ; or PCR+ or sAg for hepatitis C; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV 1 and hepatitis C by nucleic acid testing (NAT) within 30 days of apheresis collection. In the case that T pallidum antibody tests are positive, donors must:

    • Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history
    • Have completed effective antibiotic therapy to treat syphilis
    • Have a documented negative non treponemal test (such as RPR) or in the case of a positive non treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease
  4. Must be 6/6 matched sibling donor as determined by HLA typing
  5. Female donors of child-bearing potential must have a negative serum or urine beta-HCG test within three weeks of mobilization
  6. Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate
  7. Agreeable to 2nd donation of Peripheral blood stem cell (PBPC) (or bone marrow harvest) in the event of graft failure
  8. The donor or legal guardian greater than 18 years of age, capable of signing an institutional review board (IRB-approved consent form.

Donor Exclusion Criteria

  1. Evidence of active infection or viral hepatitis
  2. HIV positive
  3. Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis
  4. Lactating female

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01660607


Contacts
Layout table for location contacts
Contact: Melanie Gaudinez 650-725-4983 mgaudinez@stanford.edu

Locations
Layout table for location information
United States, California
Stanford University School of Medicine Palo Alto, California, United States Recruiting
Palo Alto, California, United States, 94305
Contact: Melanie Gaudinez    650-725-4983    mgaudinez@stanford.edu   
Sub-Investigator: Rajni Agarwal-Hashmi         
Sub-Investigator: Sally Arai         
Sub-Investigator: Jonathan Benjamin         
Sub-Investigator: Laura Johnston         
Sub-Investigator: Robert Lowsky         
Sub-Investigator: Robert S Negrin         
Sub-Investigator: Kevin Sheehan         
Sub-Investigator: Judith Anne Shizuru         
Sub-Investigator: David Miklos         
Sub-Investigator: Wen-Kai Weng         
Principal Investigator: Everett Meyer         
Sponsors and Collaborators
Everett Meyer
National Institutes of Health (NIH)
Investigators
Layout table for investigator information
Principal Investigator: Everett Meyer Stanford University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Everett Meyer, Assistant Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier: NCT01660607     History of Changes
Other Study ID Numbers: IRB-21257
SU-09142011-8407 ( Other Identifier: Stanford University )
BMT236 ( Other Identifier: OnCore )
First Posted: August 8, 2012    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Myelodysplastic Syndromes
Preleukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Lymphoma, Non-Hodgkin
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoma
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders